Search Result

Results for "

TMZ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Autophagy (2) DNA Alkylator/Crosslinker (4) DNA/RNA Synthesis (2) Dopamine Receptor (1) Drug Derivative (1) Drug Metabolite (3) HDAC (3) Histone Methyltransferase (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) PARP (1) Phosphatase (1) PROTACs (1) Reference Standards (2) Somatostatin Receptor (2)
By Research Areas:	Cancer (19) Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17364

Temozolomide 130+ Cited Publications NSC 362856; CCRG 81045; TMZ	DNA Alkylator/Crosslinker Autophagy Apoptosis	Cancer
Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects .

HY-163317A

*MMC(TMZ)-TOC TFA*	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC TFA has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC TFA targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC TFA can be used for the research of cancer .

HY-119696

MTIC	Drug Metabolite	Neurological Disease Cancer
MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity .

HY-17364R

Temozolomide (Standard) NSC 362856 (Standard); CCRG 81045 (Standard); TMZ (Standard)	Reference Standards DNA Alkylator/Crosslinker Autophagy Apoptosis	Cancer
Temozolomide (Standard) is the analytical standard of Temozolomide. This product is intended for research and analytical applications. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects .

HY-163317

*MMC(TMZ)-TOC*	Somatostatin Receptor	Cancer
MMC(TMZ)-TOC has high binding affinity and selectivity for somatostatin receptor subtype-2 (SSTR2). MMC(TMZ)-TOC targets delivery of TMZ to SSTR2-positive tumor cells. MMC(TMZ)-TOC can be used for the research of cancer .

HY-115690

K-TMZ	Drug Derivative	Cancer
K-TMZ is a derivative of methyl ketone, which exhibits antitumor efficacy against O ⁶ -methylguanine DNA methyltransferase (MGMT) deficient cell. K-TMZ can be used for research of glioblastoma .

HY-169433

Naph-Se-TMZ	PROTACs HDAC	Cancer
Naph-Se-TMZ is a PROTAC-like HDAC1 degrader. Naph-Se-TMZ can reduce the total HDAC activity in glioma cells and enhance the inhibitory effect of Temozolomide (HY-17364). Naph-Se-TMZ consists of the target protein ligand (red part) Temozolomide (HY-17364), the DNA-targeting intercalator (blue part) Nitro-Naphthalimide-C2-acylamide (HY-169437) and the molecular linker (black part). At the same time, the active control of the target protein ligand is: Temozolomide-amino hydrochloride (HY-169439), and the DNA targeting intercalator + linker is: NNISC-2 (HY-169438) .

HY-169002

PP5-IN-2	Phosphatase	Cancer
PP5-IN-2 is an orally active and selective protein phosphatase 5 (PP5) inhibitor with an IC₅₀ value of 0.9 μM. PP5-IN-2 activates p53 and downregulates cyclin D1 and MGMT, which shows potency in cell cycle arrest and reverses Temozolomide (TMZ) (HY-17364) resistance in the U87 MG cell line. PP5-IN-2 effectively inhibits tumor growth in the xenograft mouse model .

HY-119696S

MTIC-d3	Isotope-Labeled Compounds Drug Metabolite	Neurological Disease Cancer
MTIC-d₃ is deuterium labeled MTIC. MTIC is the active metabolite of Temozolomide (TMZ). MITC has lower bioavailability in the brain compared with TMZ, because the agent’s permeability through biological barriers and tumor cell membranes affects bioavailability. MITC exhibits low affinity to biological membrane .

HY-169439

Temozolomide-amino hydrochloride	Ligands for Target Protein for PROTAC HDAC	Cancer
Temozolomide-amino hydrochloride (compound 8) is an activity control for the target protein ligand of Naph-Se-TMZ (HY-169433) .

HY-119696R

MTIC (Standard)	Reference Standards Drug Metabolite	Neurological Disease Cancer
MTIC (Standard) is the analytical standard of MTIC. This product is intended for research and analytical applications. MTIC, the active metabolite of Temozolomide (TMZ), is a DNA alkylating agent. MTIC has antitumor activity [1][2][3][4].

HY-164402

NSC-124854	DNA/RNA Synthesis	Cancer
NSC-124854 is a DNA polymerase β (Pol-β) inhibitor with an IC₅₀ of 5.3 μM. NSC-124854 has antitumor activity .

HY-169437

Nitro-Naphthalimide-C2-acylamide	DNA Alkylator/Crosslinker	Cancer
Nitro-Naphthalimide-C2-acylamide is a DNA intercalator. Nitro-Naphthalimide-C2-acylamide can be used for the synthesis of PROTAC-like Naph-Se-TMZ (HY-169433) .

HY-169438

NNISC-2	DNA Alkylator/Crosslinker	Cancer
NNISC-2 (compound 4) is a DNA intercalator-linker conjugate of Naph-Se-TMZ (HY-169433), which is composed of DNA intercalator (blue part) Nitro-Naphthalimide-C2-acylamide (HY-169437) and a linker (black part) .

HY-149003

PARP1-IN-10	PARP Apoptosis	Cancer
PARP1-IN-10 (compound 12c) is a no-cytotoxicity and potent PARP1 inhibitor with an IC₅₀ value of 50.62 nM in vitro. PARP1-IN-10 causes cell cycle arrest at G2/M phase and apoptosis, and enhances the cytotoxicity of temozolomide (TMZ) .

HY-B0896

Triacetin Glyceryl triacetate; 1,2,3-Triacetoxypropane	Apoptosis HDAC	Cancer
Triacetin (Glyceryl triacetate) is a synthetic compound that is a triester of glycerol and acetic acid, orally active. Triacetin increases acetate bioavailability in glioma cells. Triacetin induces glioma cell growth arrest and Apoptosis. Triacetin freely crosses the blood brain barrier/plasma membrane. Triacetin increases histone acetylation and enhances Temozolomide (HY-17364) (TMZ) chemotherapeutic efficacy .

HY-101349

L 741742	Dopamine Receptor Apoptosis	Neurological Disease Cancer
L 741742 is a dopamine receptor D4 (DRD4) antagonist that selectively inhibits glioblastomas (GBM) growth in vitro and in vivo, synergyed with Temozolomide (TMZ) (HY-17364). L 741742 disrupts in effectors PDGFRβ/ERK1/2 and mTOR signaling. Additionally, L 741742 disrupts endolysosmal function compromising the autophagy-lysosomal degradation pathway, followed by G0/G1 cell cycle arrest and Apoptosis. L 741742 is promising for research of GBM and neurogenesis .

HY-162384

EPIC-0628	Histone Methyltransferase	Cancer
EPIC-0628 is an inhibitor of the HOTAIR-EZH2 interaction and promotes ATF3 expression. The long noncoding RNA HOTAIR has been found to regulate glioblastoma (GBM) progression and mediate DNA damage repair (DDR) by interacting with the catalytic subunit EZH2 of PRC2. EPIC-0628 also inhibits the ATF3-p38-E2F1 DDR pathway to inhibit the HR pathway and upregulates CDKN1A (p21) expression, causing cell cycle arrest. EPIC-0628 also synergizes with Temozolomide (TMZ) (HY-17364) to enhance its in vivo potency .

HY-15588

L189 3 Publications Verification	DNA/RNA Synthesis	Cancer
L189 is a DNA ligase inhibitor. L189 has inhibition effect for DNA Ligase I, III and IV with IC₅₀ values of 5 μM, 9 μM and 5 μM, respectively. L189 has no cytotoxicity and individually increase cell death. L189 can be used for the research of cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0896

Triacetin Glyceryl triacetate; 1,2,3-Triacetoxypropane	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Apoptosis HDAC
Triacetin (Glyceryl triacetate) is a synthetic compound that is a triester of glycerol and acetic acid, orally active. Triacetin increases acetate bioavailability in glioma cells. Triacetin induces glioma cell growth arrest and Apoptosis. Triacetin freely crosses the blood brain barrier/plasma membrane. Triacetin increases histone acetylation and enhances Temozolomide (HY-17364) (TMZ) chemotherapeutic efficacy .

Cat. No.	Product Name	Chemical Structure

HY-119696S

MTIC-d3
MTIC-d₃ is deuterium labeled MTIC. MTIC is the active metabolite of Temozolomide (TMZ). MITC has lower bioavailability in the brain compared with TMZ, because the agent’s permeability through biological barriers and tumor cell membranes affects bioavailability. MITC exhibits low affinity to biological membrane .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

TMZ

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products